The panel will feature three key opinion leaders (KOLs) in the fields of hepatology, endocrinology and radiology sharing their unique perspectives on managing Metabolic-Associated Steatotic Liver Disease (MASLD).
The KOL panelists will include:
The invitation-only clinical discussion will be moderated by ENDRA, and the opinions expressed are those of the independent KOL participants and not of ENDRA or the KOLs' institutions.
'We are delighted to be attending the prestigious AASLD The Liver Meeting and contributing to the topical discussion of early detection and management of MASLD. The assembled panel of multidisciplinary experts are highly respected in their respective fields and will provide diverse perspectives on the management of this disease today and in the future,' stated
'With the near-term prospect of therapeutics for treating steatotic liver disease coming to market, there is a pressing clinical need for a non-invasive and cost-effective tool to screen and monitor patients,' he added. 'We believe this provides a tremendous opportunity for ENDRA's technology, which has the ability to assess liver fat at the point-of-patient care and may potentially help improve the health of millions of people.'
ENDRA will also be showcasing its
About
Forward-Looking Statements
All statements in this press release that are not based on historical fact are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as 'approximate,' 'anticipate,' 'attempt,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'future,' 'goal,' 'hope,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'project,' 'seek,' 'should,' 'will,' 'would,' or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing for receipt of required regulatory approvals and product launches; future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; ENDRA's ability to find and maintain development partners; market acceptance of ENDRA's technology and the amount and nature of competition in its industry and ENDRA's ability to protect its intellectual property. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA's business plans; the ability to find and maintain development partners; market acceptance of ENDRA's technology and the amount and nature of competition in its industry; ENDRA's ability to protect its intellectual property and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the Company's most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the
Contact:
Irina Pestrikova
Email: investors@endrainc.com
Web: www.endrainc.com
Tel: (310) 691-7100
Email: YBriggs@lhai.com
(C) 2023 Electronic News Publishing, source